OncoMatch/Clinical Trials/NCT06791148
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Is NCT06791148 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including albumin-bound paclitaxel and AK112 for gastric cancer.
Treatment: albumin-bound paclitaxel · AK112 — The study aims to evaluate the efficacy and safety of the combination of albumin-bound paclitaxel and AK112 with low-dose radiotherapy in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment — first-line
failed first-line standard treatment
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Platelets ≥ 90 x 10^9/L; Hemoglobin ≥ 80 g/L
Kidney function
Serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 60 ml/min
Liver function
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN
Cardiac function
Cardiac enzyme levels within normal range (minor lab abnormalities deemed not clinically significant by the investigator are allowed)
Adequate organ function is determined by the following criteria: ANC ≥ 1.5 x 10^9/L; Platelets ≥ 90 x 10^9/L; Hemoglobin ≥ 80 g/L; Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN; Serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 60 ml/min; Good coagulation function, defined as INR or PT ≤ 1.5x ULN; Cardiac enzyme levels within normal range (minor lab abnormalities deemed not clinically significant by the investigator are allowed)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify